Viaderma

Viaderma EBIT Growth

The Year-over-Year EBIT Growth of Viaderma (VDRM) as of Nov 2, 2026 is -569.15 %. In the previous year, Year-over-Year EBIT Growth was -24.44 % — a change of 2,228.95% (lower).

EBIT Growth

-569.15 %

YoY

2,228.95%

Last updated:

Year-over-Year EBIT Growth of Viaderma is 2024 -569.15 % . Year-over-Year EBIT Growth of Viaderma was 2023 -24.44 % . It decreases by 2,228.95% lower compared to the previous year.

The Viaderma EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
-565.59 USD
Jan 1, 2018
-19.73 USD
Jan 1, 2019
52.46 USD
Jan 1, 2020
79.08 USD
Jan 1, 2021
564.30 USD
Jan 1, 2022
-25.27 USD
Jan 1, 2023
-24.44 USD
Jan 1, 2024
-569.15 USD
The Viaderma EBIT Growth history
YEAREBIT GrowthYoY
-569.15 %+2,228.95%
-24.44 %-3.31%
-25.27 %-104.48%
564.30 %+613.61%
79.08 %+50.74%
52.46 %-365.91%
-19.73 %-96.51%
-565.59 %-1,673.43%
35.95 %-64.59%
101.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viaderma Stock analysis

What does Viaderma do? ViaDerma, Inc. generates revenue through the manufacturing and sale of pharmaceutical products, primarily its lead product Vitastem, a topical antibiotic brand. The company sells Vitastem directly to local medical practitioners and patients in clinics within the Los Angeles area, focusing on treating various skin conditions. Additionally, ViaDerma licenses its proprietary transdermal delivery technology, which enables rapid transfer of active ingredients through the skin for immediate localized therapy. The company also develops products in anti-aging skin care, pain management, hair-loss, and toenail fungus, though these are not yet commercialized. ViaDerma, Inc. operates through its subsidiary ViaDerma, II Inc., which supports the development and commercialization of its product portfolio. The company's revenue streams include direct sales of Vitastem to healthcare providers and patients, as well as licensing fees from its transdermal technology. The primary market segments are medical practitioners and patients seeking treatments for skin ailments in the Los Angeles region, with future growth potential in emerging product categories like anti-aging and hair-loss solutions. The company's business model centers on proprietary technology that differentiates its products, allowing for faster and more effective treatment delivery. Vitastem is the cornerstone of its current revenue, while the transdermal technology serves as a complementary asset for both current and future product lines. This approach enables ViaDerma to target specific medical needs with localized solutions, primarily in the Los Angeles market, while expanding into new therapeutic areas through its pipeline. Viaderma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viaderma stock

Year-over-Year EBIT Growth of Viaderma is -569.15 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Viaderma since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Viaderma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Viaderma

All Key Metrics — Viaderma